Royalty Pharma (FRA:RPD) Interest Expense: €-289 Mil (TTM As of Mar. 2026)

What is Royalty Pharma Interest Expense?

Royalty Pharma FRA:RPD -1.91% 67 Interest Expense is €-289 Mil as of Mar. 2026. GuruFocus rates FRA:RPD with a GF Score™ of 67/100 and a GF Value™ of €32.32 (Significantly Overvalued). The stock has 10 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Royalty Pharma's interest expense for the three months ended in Mar. 2026 was € -81 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was €-289 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Royalty Pharma's Operating Income for the three months ended in Mar. 2026 was € 547 Mil. Royalty Pharma's Interest Expense for the three months ended in Mar. 2026 was € -81 Mil. Royalty Pharma's Interest Coverage for the quarter that ended in Mar. 2026 was 6.75. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Royalty Pharma (FRA:RPD) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Royalty Pharma's Interest Expense for the three months ended in Mar. 2026 was €-81 Mil. Its Operating Income for the three months ended in Mar. 2026 was €547 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was €7,419 Mil.

Royalty Pharma's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Mar. 2026 )	/	Interest Expense (Q: Mar. 2026 )
	=	-1	*	547.096	/	-81.07
	=	6.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Royalty Pharma Interest Expense Historical Data

* Premium members only.

The historical data trend for Royalty Pharma's Interest Expense can be seen below:

Royalty Pharma Interest Expense Chart

Royalty Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Interest Expense

Get a 7-Day Free Trial

-147.04

-177.44

-171.65

-215.36

-262.75

Royalty Pharma Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Interest Expense	Get a 7-Day Free Trial															-60.37	-59.54	-67.79	-80.42	-81.07

67GF Score

Royalty Pharma PLC FRA:RPD

Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Royalty Pharma Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-289 Mil.

Frequently Asked Questions Learn more about Interest Expense →

What does a Interest Expense of €-289 Mil mean?

Royalty Pharma (FRA:RPD) has a Interest Expense of €-289 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Royalty Pharma and its competitors.

Is Royalty Pharma's Interest Expense too high?

Royalty Pharma's current Interest Expense is €-289 Mil. Overall, Royalty Pharma has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Royalty Pharma's Interest Expense compare to ROIV and MRNA?

Royalty Pharma's Interest Expense of €-289 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Interest Expense for a Biotechnology company?

A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Interest Expense mean?

A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Royalty Pharma and its competitors. Royalty Pharma's current Interest Expense is €-289 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Royalty Pharma stock overvalued right now?

Based on GuruFocus' analysis, Royalty Pharma (FRA:RPD) is currently considered Significantly Overvalued. The stock's GF Value™ is €32.32, compared to a current price of €47.73 — trading 47.7% above its estimated fair value. The current Interest Expense is €-289 Mil. Royalty Pharma's overall GF Score™ is 67/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Interest Expense calculated?

Interest Expense is calculated from a company's financial statements. For Royalty Pharma (FRA:RPD), the current Interest Expense is €-289 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Royalty Pharma (FRA:RPD) Overvalued in 2026?

Based on GuruFocus' analysis, Royalty Pharma stock appears to be overvalued. The current stock price of €47.73 is trading 47.7% above its estimated GF Value™ of €32.32. GuruFocus considers Royalty Pharma to be Significantly Overvalued.

Key valuation signals for FRA:RPD:

Interest Expense: €-289 Mil
GF Value™: €32.32 vs. price of €47.73 (47.7% above fair value)
GF Score™: 67/100 with 10 warning signs

No single metric tells the full story. See the FRA:RPD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Royalty Pharma Business Description

Industry Healthcare Biotechnology

Comparable Companies ROIV MRNA BNTX INCY INSM ONC ASND JAZZ BBIO EXEL VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD XKRX:068270 HKSE:02269

Other Exchanges RPRX:USA

Address 110 East 59th Street, New York, NY, USA, 10022

Website https://www.royaltypharma.com

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

67GF Score

Get the complete analysis for FRA:RPD

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€47.73

Price

€32.32

GF Value

View FRA:RPD Analysis

See Interest Expense data for all stocks →